x
- Home
- About Diabetes
- Services
- Diabetes Mellitus Modeling Solutions
- R&D Services for Diabetes Mellitus and Diabetic Complications
- By Drug Development Process
- About Us
- Careers
- Contact Us
Cat. No.: DAB-0011856
| Product Information | |
|---|---|
| Clonality | Monoclonal |
| Isotype | IgG |
| Host Species | Rabbit |
| Reactivity | Human |
| Applications | WB |
| Product Description | Monoclonal antibody is produced by immunizing animals with a synthetic peptide corresponding to residues near the carboxy terminus of human C/EBPβ protein. |
| Format | Liquid |
| Purity | Affinity purity |
| Target Information | |
|---|---|
| Target Name | CEBPB |
| UniProt No. | P17676 |
| Gene ID | 1051 |
| Gene Description | C/EBPβ is a member of the transcription factor family of CCAAT/enhancer-binding proteins that are critical for cellular differentiation and function. There are various N-terminally truncated C/EBPβ isoforms: full-length C/EBPβ, C/EBPβ-LAP, and C/EBPβ-LIP. In triple-negative breast cancer cells, aerobic glycolysis was shown to control the expression of C/EBPβ-LAP, which in turn stimulates the expression of granulocyte colony-stimulating factor and granulocyte macrophage colony-stimulating factor. These factors are secreted from the cancer cells to promote myeloid-derived suppressor cell development in the tumor microenvironment, thereby suppressing anti-tumor immunity. In addition, research studies showed that decreased C/EBPβ-LIP expression delays age-related phenotypes in mice, suggesting a potential role for C/EBPβ-LIP in aging. |
| Shipping & Storage | |
|---|---|
| Shipping | Shipped at 4 °C. |
| Storage Instructions | Store at –20 °C. Do not aliquot the antibody. |
| Storage Buffer | Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 µg/mL BSA, 50% glycerol, and less than 0.02% sodium azide. |
Ace Therapeutics has a team of experts in the field of endocrine and metabolic research, aiming to provide innovative preclinical contract research solutions to cope with diabetes and its complications. We provide customized solutions and technical support, enabling the transformation of promising concepts into innovative treatments, thus accelerating the drug development process of diabetes.
